For adults with type 2 diabetes starting injectable treatment, GLP-1 receptor agonists are linked to a 44% lower risk of severe low blood sugar episodes compared to basal insulin over two years.
Mechanism
Synthesis from 1 study
GLP-1 drugs tell the pancreas to release insulin only when blood sugar is high, and they tell the liver to stop releasing sugar when it's not needed. This keeps blood sugar from dropping too low, unlike basal insulin, which keeps pushing sugar into cells even when levels are already low.
Most probable mechanism
GLP-1 drugs make the pancreas release insulin only when blood sugar is high, and they stop the liver from releasing too much sugar, so blood sugar doesn't drop too low.
GLP-1 receptor activation on pancreatic beta cells enhances glucose-dependent insulin secretion, increasing insulin release only when blood glucose levels are elevated
GLP-1 receptor activation on pancreatic alpha cells suppresses glucagon secretion in a glucose-dependent manner, reducing hepatic glucose production during low or normal blood glucose states
The combined effect of targeted insulin release and suppressed glucagon action stabilizes blood glucose levels, minimizing the occurrence of severe hypoglycemia
Evidence from Studies
Supporting (1)
Community contributions welcome
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.